CDK2 inhibitors

1. A method for the treatment of cancer in a subject in need thereof, wherein the cancer is breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer or thyroid cancer, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is -L 1 -(5-10 membered heteroaryl) or -L 1 -(C 6 -C 12 aryl), where said 5-10 membered heteroaryl or C 6 -C 12 aryl is optionally substituted by one or more R 4 ;

R 2 and R 3 are independently H, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, -L 2 -(C 3 -C 7 cycloalkyl) or -L 2 -(4-7 membered heterocyclyl), where each said C 1 -C 6 alkyl and C 1 -C 6 fluoroalkyl is optionally substituted by one or more R 5 and each said C 3 -C 7 cycloalkyl and 4-7 membered heterocyclyl is optionally substituted by one or more R 6 ; or

R 2 and R 3 are taken together with the N-atom to which they are attached to form a 4-6 membered heterocyclyl optionally containing an additional heteroatom selected from O, N(R 7 ) and S(O) q as a ring member, where said 4-6 membered heterocyclyl is optionally substituted by one or more R 8 ;

each L 1 and L 2 is independently a bond or a C 1 -C 2 alkylene optionally substituted by one or more R 9 ;

each R 4 is independently F, Cl, OH, CN, NR 10 R 11 , C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy, C 3 -C 8 cycloalkyl, C(O)NR 10 R 11 , SO 2 R 12 , SO(═NH)R 12 or SO 2 NR 10 R 11 , where each C 1 -C 4 alkyl and C 1 -C 4 fluoroalkyl is optionally substituted by one or more R 13 ;

each R 5 is independently OH, C 1 -C 4 alkoxy or NR 10 R 11 ;

each R 6 is independently F, OH, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy or NR 16 R 11 , where each C 1 -C 4 alkyl and C 1 -C 4 fluoroalkyl is optionally substituted by one or more R 13 ;

R 7 is H, C 1 -C 4 alkyl or C(O)—C 1 -C 4 alkyl;

each R 8 is independently F, OH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy or CN;

each R 9 is independently F, OH or C 1 -C 2 alkyl;

each R 10 and R 11 is independently H or C 1 -C 4 alkyl;

each R 12 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl;

each R 13 is independently OH, C 1 -C 4 alkoxy or NR 14 R 15 ;

each R 14 and R 15 is independently H or C 1 -C 4 alkyl; and

q is 0, 1 or 2.

2. The method of claim 1 , wherein the cancer is (a) breast cancer or ovarian cancer; (b) characterized by amplification or overexpression of cyclin E1 (CCNE1) or cyclin E2 (CCNE2); or (c) both (a) and (b).

3. The method of claim 1 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan ylcarbamate, or a pharmaceutically acceptable solvate thereof.

4. The method of claim 1 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan ylcarbamate.

5. The method of claim 1 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate monohydrate.

6. The method of claim 1 , wherein the cancer is breast cancer selected from the group consisting of hormone receptor positive (HR-positive) breast cancer, human epidermal growth factor receptor 2 negative (HER2-negative) breast cancer, and triple negative breast cancer (TNBC).

7. The method of claim 1 , wherein the cancer is lung cancer selected from the group consisting of non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), squamous cell carcinoma, and adenocarcinoma.

8. The method of claim 1 , wherein the subject is human.

9. A method for the treatment of abnormal cell growth in a subject in need thereof, wherein the abnormal cell growth is breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer or thyroid cancer, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I):

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is -L 1 -(5-10 membered heteroaryl) or -L 1 -(C 6 -C 12 aryl), where said 5-10 membered heteroaryl or C 6 -C 12 aryl is optionally substituted by one or more R 4 ;

R 2 and R 3 are independently H, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, -L 2 -(C 3 -C 7 cycloalkyl) or -L 2 -(4-7 membered heterocyclyl), where each said C 1 -C 6 alkyl and C 1 -C 6 fluoroalkyl is optionally substituted by one or more R 5 and each said C 3 -C 7 cycloalkyl and 4-7 membered heterocyclyl is optionally substituted by one or more R 6 ; or

R 2 and R 3 are taken together with the N-atom to which they are attached to form a 4-6 membered heterocyclyl optionally containing an additional heteroatom selected from O, N(R 7 ) and S(O) q as a ring member, where said 4-6 membered heterocyclyl is optionally substituted by one or more R 8 ;

each L 1 and L 2 is independently a bond or a C 1 -C 2 alkylene optionally substituted by one or more R 9 ;

each R 4 is independently F, Cl, OH, CN, NR 10 R 11 , C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy, C 3 -C 8 cycloalkyl, C(O)NR 10 R 11 , SO 2 R 12 , SO(═NH)R 12 or SO 2 NR 19 R 11 , where each C 1 -C 4 alkyl and C 1 -C 4 fluoroalkyl is optionally substituted by one or more R 13 ;

each R 5 is independently OH, C 1 -C 4 alkoxy or NR 10 R 11 ;

each R 6 is independently F, OH, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy or NR 10 R 11 , where each C 1 -C 4 alkyl and C 1 -C 4 fluoroalkyl is optionally substituted by one or more R 13 ;

R 7 is H, C 1 -C 4 alkyl or C(O)—C 1 -C 4 alkyl;

each R 8 is independently F, OH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy or CN;

each R 9 is independently F, OH or C 1 -C 2 alkyl;

each R 10 and R 11 is independently H or C 1 -C 4 alkyl;

each R 12 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl;

each R 13 is independently OH, C 1 -C 4 alkoxy or NR 14 R 15 ;

each R 14 and R 15 is independently H or C 1 -C 4 alkyl; and

q is 0, 1 or 2.

10. The method of claim 9 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate, or a pharmaceutically acceptable solvate thereof.

11. The method of claim 9 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate.

12. The method of claim 9 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate monohydrate.

13. A method for the treatment of abnormal cell growth in a subject in need thereof, wherein the abnormal cell growth is breast cancer, ovarian cancer, bladder cancer, uterine cancer, prostate cancer, lung cancer, esophageal cancer, head and neck cancer, colorectal cancer, kidney cancer, liver cancer, pancreatic cancer, stomach cancer or thyroid cancer, comprising administering to the subject an amount of a compound of Formula (I):

or a pharmaceutically acceptable salt or solvate thereof, wherein:

R 1 is -L 1 -(5-10 membered heteroaryl) or -L 1 -(C 6 -C 12 aryl), where said 5-10 membered heteroaryl or C 6 -C 12 aryl is optionally substituted by one or more R 4 ;

R 2 and R 3 are independently H, C 1 -C 6 alkyl, C 1 -C 6 fluoroalkyl, -L 2 -(C 3 -C 7 cycloalkyl) or -L 2 -(4-7 membered heterocyclyl), where each said C 1 -C 6 alkyl and C 1 -C 6 fluoroalkyl is optionally substituted by one or more R 5 and each said C 3 -C 7 cycloalkyl and 4-7 membered heterocyclyl is optionally substituted by one or more R 6 ; or

R 2 and R 3 are taken together with the N-atom to which they are attached to form a 4-6 membered heterocyclyl optionally containing an additional heteroatom selected from O, N(R 7 ) and S(O) q as a ring member, where said 4-6 membered heterocyclyl is optionally substituted by one or more R 8 ;

each L 1 and L 2 is independently a bond or a C 1 -C 2 alkylene optionally substituted by one or more R 9 ;

each R 4 is independently F, Cl, OH, CN, NR 10 R 11 , C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy, C 3 -C 8 cycloalkyl, C(O)NR 10 R 11 , SO 2 R 12 , SO(═NH)R 12 or SO 2 NR 10 R 11 , where each C 1 -C 4 alkyl and C 1 -C 4 fluoroalkyl is optionally substituted by one or more R 13 ;

each R 5 is independently OH, C 1 -C 4 alkoxy or NR 10 R 11 ;

each R 6 is independently F, OH, C 1 -C 4 alkyl, C 1 -C 4 fluoroalkyl, C 1 -C 4 alkoxy, C 1 -C 4 fluoroalkoxy or NR 10 R 11 , where each C 1 -C 4 alkyl and C 1 -C 4 fluoroalkyl is optionally substituted by one or more R 13 ;

R 7 is H, C 1 -C 4 alkyl or C(O)—C 1 -C 4 alkyl;

each R 8 is independently F, OH, C 1 -C 4 alkyl, C 1 -C 4 alkoxy or CN;

each R 9 is independently F, OH or C 1 -C 2 alkyl;

each R 10 and R 11 is independently H or C 1 -C 4 alkyl;

each R 12 is C 1 -C 4 alkyl or C 3 -C 6 cycloalkyl;

each R 13 is independently OH, C 1 -C 4 alkoxy or NR 14 R 15 ;

each R 14 and R 15 is independently H or C 1 -C 4 alkyl; and

q is 0, 1 or 2,

in combination with an additional anti-cancer therapeutic agent.

14. The method of claim 13 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate, or a pharmaceutically acceptable solvate thereof.

15. The method of claim 13 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate.

16. The method of claim 13 , wherein the compound of Formula (I) is (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate monohydrate.

17. The method of claim 1 , wherein the compound of Formula (I) is a pharmaceutically acceptable solvate of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1 H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate.

18. The method of claim 1 , wherein the solvate is a hydrate.

19. The method of claim 1 , wherein the compound of Formula (I) is a hydrate of (1R, 3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1 H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate.

20. The method of claim 9 , wherein the compound of Formula (I) is a pharmaceutically acceptable solvate of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1 H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate.

21. The method of claim 9 , wherein the solvate is a hydrate.

22. The method of claim 9 , wherein the solvate is a hydrate of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate.

23. The method of claim 13 , wherein the compound of Formula (I) is a pharmaceutically acceptable solvate of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-am ino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate.

24. The method of claim 13 , wherein the solvate is a hydrate.

25. The method of claim 13 , wherein the solvate is a hydrate of (1R,3S)-3-[3-({[3-(methoxymethyl)-1-methyl-1H-pyrazol-5-yl]carbonyl}-amino)-1H-pyrazol-5-yl]cyclopentyl propan-2-ylcarbamate.